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The induction of antiviral effector proteins as part of a homeostatically controlled innate
immune response to infection plays a critical role in limiting the propagation and
transmission of respiratory pathogens. However, the prolonged induction of this
immune response can lead to lung hyperinflammation, tissue damage, and respiratory
failure. We hypothesized that tissues exposed to the constant threat of infection may
constitutively express higher levels of antiviral effector proteins to reduce the need to
activate potentially harmful innate immune defences. By analysing transcriptomic data
derived from a range of human tissues, we identify lung tissue to express constitutively
higher levels of antiviral effector genes relative to that of other mucosal and non-mucosal
tissues. By using primary cell lines and the airways of rhesus macaques, we show the
interferon-stimulated antiviral effector protein TRIM22 (TRIpartite Motif 22) to be
constitutively expressed in the lung independently of viral infection or innate immune
stimulation. These findings contrast with previous reports that have shown TRIM22
expression in laboratory-adapted cell lines to require interferon stimulation. We
demonstrate that constitutive levels of TRIM22 are sufficient to inhibit the onset of
human and avian influenza A virus (IAV) infection by restricting the onset of viral
transcription independently of interferon-mediated innate immune defences. Thus, we
identify TRIM22 to confer a pre-existing (intrinsic) intracellular defence against IAV infection
in cells derived from the respiratory tract. Our data highlight the importance of tissue-
specific and cell-type dependent patterns of pre-existing immune gene expression in the
intracellular restriction of IAV from the outset of infection.
Keywords: TRIM22, influenza, intrinsic immunity, antiviral defence, respiratory tractgy | www.frontiersin.org September 2021 | Volume 11 | Article 6897071
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Exposure to viral pathogens is a constant threat to all living things
and vertebrates have evolved multiple lines of defence to suppress
infection, propagation, and transmission to new hosts. If viruses
succeed in penetrating non-specific barrier defences, the
activation of pattern recognition receptors (PRRs) by pathogen-
and damage-associated molecular patterns (PAMPs and DAMPs,
respectively) leads to the activation of innate immune defences.
This culminates in the secretion of cytokines (including
interferons) and the induction of interferon stimulated gene
(ISG) products (Killip et al., 2015; Pulendran and Maddur,
2015). ISGs include a wide range of antiviral effector proteins,
and their induced expression from low basal levels to high
functional levels plays an important role in resolving infection
(Schoggins et al., 2011; Durbin et al., 2013; Schoggins et al., 2014).
However, the induction of this antiviral response necessitates
pathogen detection. In the case of wild-type influenza A virus
(IAV) this requires the detection of aberrant viral RNAs (vRNAs)
produced during viral replication by PRRs for optimal induction
(Tapia et al., 2013; Killip et al., 2017; Vasilijevic et al., 2017;
Russell et al., 2019). Accordingly, the delayed activation of innate
immune defences provides a window of opportunity for viral
pathogens to express immunosuppressive genes, which can
inhibit or dampen the efficacy of host immune defences (Hale
et al., 2010; Hsu, 2018). A growing body of evidence suggests that
this initial ‘gap’ in intracellular immunity is covered by
constitutively expressed (continuously transcribed and
translated) host factors that confer a pre-existing level of
immune protection to susceptible cells, often referred to as
intrinsic antiviral immunity (Bieniasz, 2004; Komatsu et al.,
2016; Wu et al., 2018).
Effectors of intrinsic immunity are expressed at sufficient
levels to confer protection from the outset of infection. As a
result, they can restrict the initiation or progress of viral
replication prior to the activation of PRRs and induction of
innate immune defences (Brass et al., 2009; Fu et al., 2015; Patil
et al., 2018). In some cases, the constitutive expression of these
antiviral host factors can occur in a species-specific and cell-type
dependent manner, which can influence host range and relative
susceptibility to infection (Bieniasz, 2004; Wu et al., 2018;
Bergantz et al., 2019). Although the importance of intrinsic
immunity in the context of retrovirus and DNA virus infection
is well established (Komatsu et al., 2016; Alandijany, 2019;
Bergantz et al., 2019), evidence to support a biological role for
intrinsic immunity during IAV infection has remained limited.
The TRIpartite Motif (TRIM) family of proteins comprise
over 70 members that participate in a range of biological
processes, including viral immune regulation (Van Tol et al.,
2017; Van Gent et al., 2018; Koepke et al., 2020). Many TRIM
proteins are upregulated in response to IFN stimulation and act
as regulators or effectors of innate immunity. Other TRIM
proteins are constitutively expressed to efficacious levels that
can act to directly restrict infecting pathogens. Notably, several
TRIM family members can confer protection against multiple
viruses, suggesting they act as key effector molecules of the
antiviral immune response (Koepke et al., 2020). For example,Frontiers in Cellular and Infection Microbiology | www.frontiersin.org 2TRIM22 has been implicated in the cellular restriction of a broad
range of viruses, including encephalomyocarditis virus [EMCV;
(Eldin et al., 2009)], hepatitis B virus [HBV; (Gao et al., 2009)],
hepatitis C virus [HCV; (Yang et al., 2016)], human
immunodeficiency virus [HIV; (Barr et al., 2008; Turrini et al.,
2015)], herpes simplex virus 1 [HSV-1; (Reddi et al., 2021)], and
IAV (Di Pietro et al., 2013). Studies have shown TRIM22 to be an
ISG, strongly upregulated by type-I and type-II IFNs (Hattlmann
et al., 2012). Accordingly, TRIM22 has been shown to inhibit
viral infection following its induced expression as an ISG by
restricting the onset of viral transcription or targeted degradation
of viral proteins (Hattlmann et al., 2012). With respect to IAV,
TRIM22 has been reported to mediate the ubiquitination and
proteasome-dependent degradation of NP, restricting IAV
propagation as an induced effector protein of the type-I IFN
response (Di Pietro et al., 2013; Pagani et al., 2018).
We hypothesized that localized patterns of immune gene
expression at portals of viral entry may confer enhanced
protection to cells susceptible to infection. We identify
TRIM22 to be among several antiviral effector proteins to be
constitutively expressed in the lung. Using primary cell lines of
lung origin and the airways of rhesus macaques, we show the
constitutive expression of TRIM22 to occur independently of
interferon-stimulation or viral infection. We demonstrate
endogenous levels of TRIM22 to be sufficient to restrict the
initiating cycle of human and avian IAV infection independently
of IFN-mediated innate immune defences. Thus, we identify
TRIM22 to confer a pre-existing (intrinsic) intracellular immune
barrier to IAV infection. Transcriptomic analysis revealed
TRIM22 to be one of a large group of antiviral host factors
that are downregulated in many laboratory-adapted cell lines
commonly used for virus research. Collectively, our data
demonstrate tissue-specific and cell-type dependent patterns of
pre-existing immune gene expression to play a previously
unappreciated role in the cellular restriction of IAV from the
outset of infection.MATERIALS AND METHODS
Animals and Ethics
No animals were directly subjected to experimentation as part of
this scientific study. All animal tissues were obtained from
material produced in previously described experiments
(Marriott et al., 2016) with permission from Public Health
England (PHE). Procedures associated with this earlier study
were approved by the PHE Ethical Review Committee (Porton
Down, UK), authorized under UK Home Office project licence
30/3083, and performed according to UK Animal (Scientific
procedures) Act 1986. 3- to 3.5-year-old male cynomolgus
macaques (Macaca fascicularis) were housed in socially
compatible groups of 4 in cages with a floor of deep litter for
foraging and a range of toys, puzzles, and DVDs for stimuli. The
colony was regularly screened and shown to be free from Herpes
B virus, Simian T-cell Lymphotropic virus, Simian retrovirus,
Simian immunodeficiency virus, Mycobacterium tuberculosis,September 2021 | Volume 11 | Article 689707
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Animals were sedated by intramuscular injection prior to
infection with ketamine hydrochloride (Marriott et al., 2016).
Animals were infected with 6x106 PFU of IAV (A/California/04/
2009 (H1N1); Cal) via intra-tracheal inoculation and euthanized
5 days post-infection (Marriott et al., 2016). Animals were
monitored for health and wellbeing throughout the study
(Marriott et al., 2016). Tissues were collected at necropsy and
fixed in 10% neutral buffered formalin, processed to paraffin wax,
and cut into 5-6 µm sections.
Quantitative Histopathology of
Cynomolgus Macaque Tissue Sections
Deparaffinised and rehydrated tissue sections were processed for
epitope retrieval using EnVision FLEX target retrieval solution
(Agilent, K8004), as per manufacturer’s instructions. Samples
were processed and stained for TRIM22 (Proteintech, 13744-1-
AP; 1/50 dilution) and FLEX haematoxylin (Agilent, K8008)
using a Autostainer Link 48 (Agilent), as per manufacturer’s
instructions. TRIM22 antibody specificity was validated by
staining sectioned MRC5 (positive control) or A549 (negative
control) cell pellets. Tissue sections were independently assessed
for TRIM22 expression by a qualified pathologist. Automated
quantitation of TRIM22 expression levels was performed using
whole-slide scans and Image-Pro Premier (Media Cybernetics),
as previously described (Leeming et al., 2015; Akram et al., 2018).
Quantitative Histopathology of Human
Tissue Sections
IHC data from anonymized human bronchus and nasopharynx
tissues stained for TRIM22 were obtained from the Human
Protein Atlas [HPA; http://www.proteinatlas.org; (Uhlen et al.,
2010; Uhlen et al., 2015)] under a Creative Commons Attribution-
ShareAlike 3.0 International License. The original images




RNA-Seq Analysis of Human Cell Lines
and Tissues
RNA-Seq data for human cell lines (HBEC3-KT, A549, HEK 293,
and HeLa) and anonymized human tissue (lung, small intestine,
esophagus, colon, liver, skin, and kidney) were obtained from
Human Protein Atlas [HPA; http://www.proteinatlas.org, version
18.1; (Uhlen et al., 2010; Uhlen et al., 2015)] or Genotype-Tissue
Expression project [GTEx; https://gtexportal.org/home/, V7;
(Carithers et al., 2015)] supported by the Common Fund of the
Office of Director of the National Institutes of Health, and by NCI,
NHGRI, NHLBI, NIDA, NIMH, and NINDS under Creative
Commons Attribution-ShareAlike 3.0 International License.
Principle Component Analysis (PCA) cluster plots were
generated using kmeans and clusplot packages and prcomp
function in R (https://www.r-project.org). Heatmaps were
generated using Prism 8 (GraphPad) or pheatmap (v1.0.12) and
cluster (v2.0.7-1) package in R.Frontiers in Cellular and Infection Microbiology | www.frontiersin.org 3Cells, Viruses, and Drugs
Primary human foetal lung fibroblast (MRC5) cells were purchased
from the European Collection of Authenticated Cell Cultures
(ECACC; 05072101). MRC5t cells are immortalized MRC5 cells
expressing the catalytic subunit of human telomerase (hTERT),
and were generated as previously described (Smith et al., 2013).
MRC5 and MRC5t cells were cultured in Dulbecco’s Modified
Eagle Medium (DMEM; Life Technologies; 41966) supplemented
with 10% foetal bovine serum (FBS; Life Technologies; 10270), 100
U/ml of penicillin and 100 mg/ml of streptomycin (P/S; Life
Technologies; 15140-122), and 1× non-essential amino acids
(NEAA; Life Technologies 11140-035). MRC5t cells were
supplemented with 5 mg/mL hygromycin B (Thermo Fisher
Scientific; 10687010) to maintain hTERT expression. MRC5t
cells were transduced with lentiviruses to express short hairpin
(sh) RNAs based on the 19-mer sequences; non-targeting control
(shCtrl; 5’-ttatcgcgcatatcacgcg-3’) or TRIM22 targeting (shTRIM22
clone B7 [3’ UTR]; 5’-TATTGGTGTTCAAGACTAT-3’, clone B8;
5’-CTGTACGCACCTGCACATT-3’, clone B9; 5’-GTGTCTTC
GGCTGCCAATA-3’), as previously described (Everett et al.,
2006). Pooled, stably transduced cells were maintained in growth
media supplemented with 0.5 µg/ml puromycin (Sigma-Aldrich;
P8833). Primary human bronchial epithelial (HBEp) cells were
purchased from Sigma-Aldrich (502-05a). hTERT and CDK4
immortalized human bronchial epithelial cells (HBEC3-KT) were
purchased the Hamon Center for Therapeutic Oncology Research
[UT Southwestern Medical Center; (Ramirez et al., 2004)]. Cells
were cultured according to supplier guidelines. Madin Darby
Canine Kidney (MDCK; a gift from Ben Hale University of
Zurich), human lung adenocarcinoma epithelial (A549; PHE
Culture Collections, 86012804), human embryonic kidney (HEK
293T; a gift from Roger Everett MRC-UoG CVR) and human
cervical carcinoma (HeLa [a gift from Juergen Hass University of
Edinburgh] or HEp2 [a gift from Roger Everett MRC-UoG CVR])
cells were cultured in DMEM with 10% FBS and P/S. All cells were
maintained at 37°C in 5% CO2. IAV strains A/WSN/1933(H1N1)
(WSN), A/Puerto Rico/8/1934(H1N1) (PR8), A/Udorn/307/1972
(H3N2) (Udorn), and A/California/04/2009(H1N1) (Cal) were
propagated in MDCK cells. A/Duck/Singapore/5/1997(H5N3)
(Duck H5N3) and A/Chicken/Italy/1067/1999(H7N1) (Chicken
H7N1) were propagated in embryonated chicken eggs. WSN titres
were calculated by immunocytochemistry (ICC) plaque assay, as
described below. PR8, Udorn, Duck H5H3 and Chicken H7N1
titres were calculated based on focus forming units (FFU), as
described below. Cells were interferon stimulated by the addition
of 100 IU/ml recombinant interferon-b (IFN-b; Merck, 407318) to
the growth media for 24 h. Ruxolitinib (Ruxo; Selleckchem; S1378)
was prepared in DMSO and used at the concentrations indicated.
Plaque, FFU, and Virus Yield Assays
For plaque assays, cells were seeded at 2 × 105 cells/well in 12-
well dishes and incubated for a minimum of 16 h prior to
infection. Cells were infected with serial dilutions of virus for 1 h
at 37°C prior to overlay with conditioned growth medium
supplemented with 1.2% Avicel (Biopolymers; RC-591), 0.1%
sodium bicarbonate (Life Technologies; 25080-060), and 0.01%September 2021 | Volume 11 | Article 689707
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processed for ICC staining at 24 to 72 hpi depending on virus
replication kinetics [as previously described (Conn et al., 2016)]
or stained with Giemsa stain (VWR; 35086). Relative plaque titre
was calculated as the plaque titre of a virus stock under the
indicated condition divided by its titre under a control condition.
For FFU assays, 1 x 105 MRCt cells were seeded onto 13mm glass
coverslips and incubated for 16 h prior to infection. Viral stocks
were serially diluted and used to infect MRC5t cells for 1 h at 37°
C prior to overlay with conditioned growth medium. Cells were
fixed at 8 hpi, immunostained for the viral protein NP, and
analyzed by immunofluorescent confocal microscopy. The total
number of cells and number of NP positive cells imaged was
determined using ImageJ from a minimum of 5-fields of view per
dilution, and the % of NP positive cells calculated. The dilution
resulting in closest to 50% infected cells was selected for
calculation of FFU and adjusted for the Poisson distribution, as
previously described (Hutchinson et al., 2008). Viral titres were
determined from a minimum of 3 independent titrations. For
virus yield assays, cells were infected with IAV (WSN) at the
indicated multiplicity of infection (MOI) for 1 h at 37°C, washed
twice with PBS, then overlaid with growth medium.
Supernatants were collected at the indicated time points post-
infection and the released virus was titred by plaque assay in
MDCK cells. Plaque diameters were measured using an
automated Celigo imaging cytometer (Nexcelom biosciences),
as per the manufacturer’s instructions.
Antibodies
Polyclonal antibodies were used to detect TRIM22 (Sigma-
Aldrich; HPA003575), Mx1 (Santa Cruz; sc-50509), GBP1
(Proteintech; 15303-1-AP), IFIH1 (Proteintech; 21775-1-AP),
TLR3 (Proteintech; 17766-1-AP), and actin (Sigma-Aldrich;
A5060). IAV hybridoma antisera were used to detect NP, M1,
and NS1, as previously described (Turnbull et al., 2016).
Monoclonal antibodies were used to detect UBA7 (AbCam;
ab133499), Actin (DSHB; 224-236-1), IFITM1 (Proteinech;
60074-1g), and IAV NP (AbCam; ab20343). Secondary
antibodies were Alexa 488 and 555 donkey anti-mouse and
-rabbit (Invitrogen; A21202, A21206, and A31572), DyLight
680- or 800-conjugated anti-rabbit (Thermo Fisher Scientific;




1 × 105 cells were seeded on 13 mm glass coverslips in 24-well
dishes and incubated for a minimum of 16 h prior to
experimentation. After treatment, cell monolayers were fixed,
permeabilized, and immunostained at the indicated time points,
as previously described (Conn et al., 2016). Nuclei were stained
with DAPI (Sigma-Aldrich, D9542). Coverslips were mounted
on glass slides using Citiflour AF1 mounting medium
(AgarScientific; R1320) and sealed with nail enamel. Samples
were examined with a Zeiss LSM 880 or LSM 710 confocal
microscope with 405, 488, 543, and 633-nm laser lines. ImagesFrontiers in Cellular and Infection Microbiology | www.frontiersin.org 4were captured under a Plan-Apochromat 63×/1.4 oil immersion
or Plan-Neofluar 20×/0.5 air objective lenses. The proportion of
IAV NP antigen positive cells was calculated from a minimum of
five wide field images, imaging more than 1000 cells per coverslip
per condition. The proportion of NP positive cells was
determined and the fold increase in NP positive cells between
IAV infected shTRIM22 and shCtrl MRC5t cells calculated for
each biological repeat.
Western Blotting
Cells were seeded at 2 × 105 cells/well in 12-well dishes and
incubated for a minimum of 16 h prior to experimentation.
Treated or infected cell monolayers were washed twice in PBS
and whole cell lysates (WCLs) collected in Laemmli buffer.
Proteins were resolved on NOVEX NU-PAGE (4-12%) Bis-
Tris gels (Invitrogen; NP0322), transferred onto 0.22 µm
nitrocellulose membranes (Amersham; 15249794), and probed
by western blotting, as previously described (Conn et al., 2016).
Membranes were imaged using an Odyssey Infrared Imager (Li-
Cor). Band intensities were quantified using Image Studio
Software (Li-Cor). Individual values were normalized to their
respective actin loading controls prior to normalization to their
respective control group (as indicated).
qRT-PCR
For viral or cellular mRNA quantitation, cells were seeded at 2 ×
105 cells/well in 12-well dishes and incubated for a minimum of
16 h prior to experimentation. Treated or infected cell
monolayers were washed once in PBS prior to RNA extraction
using an RNAeasy Plus Kit (Qiagen; 74134). mRNA was reverse
transcribed (RT) using the TaqMan Reverse Transcription
Reagents kit (Life Technologies; N8080234) with oligo (dT)
primers. Samples were analysed in triplicate using the TaqMan
Fast Universal PCRMaster Mix (Life Technologies, 4352042) and
TaqMan GAPDH (4333764F), TRIM22 (Hs01001179_m1), Mx1
(Hs00895608_m1) or ISG15 (Hs01921425_s1) specific primer-
probe (FAM/MGB; Thermo Fisher Scientific) mixes or custom
IAV (NP, M1, NS1/NEP) primer-probes mixes (Supplemental
Table S5). The DDCt method was used to normalize transcript
levels to those of GAPDH mRNA. For vRNA analysis, cells were
seeded at 4 × 105 cells/well in 6-well plates and incubated for a
minimum of 16 h prior to experimentation. For vRNA analysis,
total RNA was isolated from nuclear pellets using an RNAeasy
Plus Kit . An IAV segment 7 spec ific pr imer (5 ’-
AGCCGAGATCGCACAGAGACTT-3’) was used for reverse
transcription, as previously described (Vester et al., 2010).
Samples were analysed in triplicate using the M1 primer-probe
mix relative to a synthetic segment 7 (M) vRNA reference
standard. The segment 7 vRNA standard was produced as
previously described (Vester et al., 2010). Briefly, vRNA was
extracted from infected MDCK cells using the QIAamp Viral
RNA Mini kit (Qiagen, 52904) and extracted RNA was reverse
transcribed using the Uni12 universal IAV segment primer (5’-
AGCAAAAGCAGG-3’) and TaqMan Reverse Transcription
Reagent kit. The cDNA was used as a template to amplify the
IAV segment 7 ORF, incorporating a T7 promoter sequence that
was used to generate synthetic segment 7 vRNA using theSeptember 2021 | Volume 11 | Article 689707
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Scientific; K0441). Synthetic vRNA was purified using an
RNAeasy column and used as a reference standard for reverse
transcription and qRT-PCR analysis.RESULTS
Human Lung Tissue Is Enriched for
Constitutive ISG Expression
As the respiratory tract is a major portal for virus entry, we
hypothesized that cells in the respiratory mucosa might express
antiviral effector proteins to higher levels than cells in tissues at
less exposed locations, thereby creating localized patterns of pre-
existing antiviral defence. We reasoned that if these pre-existing
effector proteins were constitutively expressed to efficacious
levels prior to infection, they will be amongst the most
abundantly expressed antiviral proteins in healthy human tissue.
To investigate, we began by analyzing the constitutive
expression profile of 200 ISGs across a range of human tissues
derived from a mixture of cell types [Genotype-Tissue Expression
(GTEx) project; (Carithers et al., 2015; Shaw et al., 2017)]. We
analysed RNA-seq data from mucosal (lung, esophagus, colon,
and small intestine) and non-mucosal (liver, skin, and kidney)
tissues (Figure 1 and Supplemental Table S1A). We identified
tissue-specific profiles of constitutive ISG expression, with lung
tissue expressing the highest level of ISG expression relative to all
other tissues examined (Figures 1A, B). Principle component
analysis (PCA) demonstrated that not all ISGs were constitutively
expressed or expressed to equivalent levels (Figure 1C), with lung
tissue sharing the highest degree of ISG profile similarity to that of
the small intestine (Figure 1D). Notably, many of the top 50
constitutively expressed ISGs in the lung were known antiviral
host factors, including BST2, IFITM1, SAMHD1, TRIM22, and
GBP family members (Figure 1E) (Schoggins et al., 2011).
Importantly, IFN transcript levels were either not detectible or
extremely low (< 1 TPM; Figures 1F, G and Supplemental Table
S1B), indicating that these tissues were not constitutively
expressing IFN at the point of RNA extraction. While we
cannot rule out a role for tonic-IFN signalling or host
microbiota in the tissue-dependent enrichment of ISGs (Tovey
et al., 1987; Gough et al., 2012; Liu et al., 2018; Bradley et al., 2019),
our analysis identifies enriched levels of ISG expression in the lung
that could confer enhanced protection upon pathogen entry.
TRIM22 Is Constitutively Expressed at
High Levels in the Respiratory Tract
Independently of Immune Stimulus or
Virus Infection
To further explore our observation that lung tissue shows
enriched levels of antiviral gene expression, we examined the
expression profile of TRIM family members which include both
interferon-stimulated and constitutively expressed antiviral
effector proteins (Van Tol et al., 2017; Van Gent et al., 2018;
Koepke et al., 2020). We compared the profiles of TRIMFrontiers in Cellular and Infection Microbiology | www.frontiersin.org 5expression from two independently-derived lung transcriptome
data sets [GTEx project and Human Protein Atlas (HPA);
(Uhlen et al., 2010; Carithers et al., 2015; Uhlen et al., 2015)].
Our analysis identified TRIM22 to be one of the most abundantly
expressed TRIM family members in the lung (Figure 2A, red
circle; Supplemental Table S2A) independently of detectible
levels of IFN expression (Supplemental Table S1B). The
expression of TRIM22 was comparable to that of TRIM8 and
TRIM28, and higher than that of TRIM32 and TRIM41, which
have been reported to be intrinsic antiviral effectors of IAV
replication (Fu et al., 2015; Patil et al., 2018). Notably, the relative
expression levels of TRIM8, 28, 32, and 41 are not influenced by
IFN stimulation (Shaw et al., 2017). The high levels of
constitutive TRIM22 expression was surprising, since this level
of expression has been previously reported to require viral
infection or IFN stimulation (Hattlmann et al., 2012; Di Pietro
et al., 2013). We therefore investigated if this profile of
constitutive TRIM22 expression was specific to lung tissue. We
found TRIM22 expression to be enriched in the spleen, lymph
node, appendix, and lung relative to other tissues (Figure 2B, red
circle; Supplemental Table S2B). Analysis of HPA
immunohistochemistry (IHC) expression records confirmed
high levels of constitutive TRIM22 protein expression in the
nasopharynx and bronchus (Figures 2C, D). Together, these
data demonstrate that TRIM22 is expressed to high levels in the
respiratory tract relative to other tissues or TRIM
family members.
As we had identified TRIM22 to be amongst the top 50
constitutively expressed ISGs in the lung, we next analysed how
TRIM22 expression in the respiratory tract responded to viral
infection. As mice lack an orthologue to human TRIM22
(https://www.ncbi.nlm.nih.gov/homologene/?term=trim22), we
examined respiratory tissue derived from cynomolgus
macaques (Macaca fascicularis), whose TRIM22 has 92%
amino acid identity to human TRIM22. Using a validated
TRIM22 antibody (HPA; see below), we could detect TRIM22
in the respiratory tract of uninfected macaques, specifically in
epithelia of the airways, sub-mucosal glands, alveoli, and in
alveolar macrophages (Figure 2E, uninfected). To determine
whether TRIM22 expression increased during infection, we
compared healthy macaques with those infected with IAV
(A/California/04/2009 (H1N1); Cal). These macaques were
infected as part of a previous study and were confirmed to be
undergoing an innate immune response at the point of
euthanasia (Marriott et al., 2016). Automated staining and
quantitation of sectioned samples demonstrated TRIM22
expression did not increase in the respiratory tract of IAV
infected macaques relative to the control group (Figures 2E, F).
As the expression of TRIM22 in the respiratory tract
contrasted with its reported expression in many laboratory-
adapted cell lines and primary lymphocytes (Mo et al., 2007;
Hattlmann et al., 2012; Di Pietro et al., 2013), we examined
TRIM22 expression in primary human bronchial epithelial
(HBEp) cells. TRIM22 was readily detectable in unstimulated
cells by indirect immunofluorescence (Figure 2G), showing the
same predominantly nuclear localization observed by IHC inSeptember 2021 | Volume 11 | Article 689707




FIGURE 1 | Lung tissue is enriched for constitutive ISG expression relative to other mucosal and non-mucosal tissues. (A) Heat map showing the constitutive expression
profile (log2 transcripts per million; TPM) of 200 ISGs across a range of human mucosal and non-mucosal tissues; lung (n=427), small intestine (Int.; terminal ileum;
n=137), esophagus (Espho.; mucosa; n=407), colon (sigmoid; n=233), liver (n=175), skin (suprapubic; n=387), and kidney (cortex; n=45). Every second ISG labelled
(individual values shown in Supplemental Table S1A). (B) Violin plot showing tissue ISG expression profiles (as in A). Horizontal solid lines; median ISG expression per
tissue. Horizontal dotted lines; 5th and 95th percentile range per tissue. (C) Principle component (PC) analysis of ISG expression levels across all tissues (as in A).
(D) Heatmap showing clustered relationship of ISG expression levels between different tissues (as in A). (E) Violin plots showing the top 50 constitutively expressed ISGs
in the lung relative to small intestine, skin, and kidney tissues. White line; median. Box; 5th and 95th percentile range. (F) Heat map showing the expression profile (log2
TPM) of IFN-related receptors and cytokines per tissue (as in A; values shown in Supplemental Table S1B). (G) Violin plot showing IFN-related cytokine expression
profile (as in F). Horizontal solid lines; median. Horizontal dotted lines; 5th and 95th percentile range. (E, F) Paired one-way ANOVA (Friedman multiple comparison test);
p-values shown. RNA-Seq data adapted under creative commons licence from GTEx portal [https://gtexportal.org/home/; (Carithers et al., 2015)].Frontiers in Cellular and Infection Microbiology | www.frontiersin.org September 2021 | Volume 11 | Article 6897076





FIGURE 2 | TRIM22 is constitutively expressed in the respiratory tract independently of IAV infection. (A) Scatter plot showing TRIM family member expression levels
(log2 TPM) in human lung tissue derived from two independent data sources (GTEx and HPA, respectively; values shown in Supplemental Table S2A). Solid brown
line; linear regression, R-squared (R2 = 0.85). Solid black lines; 95% confidence interval. (B) Scatter plot showing TRIM22 expression levels (log2 TPM) across a range
of tissues (as in A; values shown in Supplemental Table S2B). Black line: median TRIM22 transcript expression; whisker: 5th to 95th percentile range. (C) Histological
sections of human respiratory epithelium from the upper (nasopharynx; patient ID 3624) and lower (bronchus; patient ID 3987) airway. TRIM22 is labelled by
immunohistochemistry (IHC; brown). Tissues were counterstained with haematoxylin and eosin. Scale bar 50 µm. (D) Quantitation of TRIM22 IHC staining across a
range of human tissues. Red bars highlight TRIM22 expression in cells of lung origin. (A–D) Data adapted under creative commons license from GTEx portal [https://
gtexportal.org/home/; (Carithers et al., 2015)] and Human Protein Atlas [HPA; https://www.proteinatlas.org; (Uhlen et al., 2010; Uhlen et al., 2015)]. (E) Histological
sections of uninfected or intra-tracheal influenza A virus [IAV; A/California/04/09(H1N1), Cal] infected (6x106 PFU) cynomolgus macaques at 5 days post-infection.
Tissue sections of respiratory epithelium derived from the bronchus or alveoli were stained for TRIM22 by IHC (brown) and counterstained with haematoxylin. Scale
bars; 50 and 20 µm (left and right panels, respectively). (F) Automated quantitation of TRIM22 IHC staining in uninfected or infected cynomolgus macaque respiratory
tissue from whole-slide scans (as in E). Means and SD from four uninfected and three infected animals shown. (G) Confocal images of primary human bronchial
epithelial (HBEp) cells stained for TRIM22 by indirect immunofluorescence (green). Nuclei stained with DAPI (blue). Scale bars; 10 µm (top panel) and 20 µm (bottom
panel). (H–J) Primary HBEp cells were treated with (+) or without (-) IFN-b (100 IU/ml) for 24 h. (H) qRT-PCR of TRIM22 and Mx1 mRNA transcript levels in control or
IFN treated HBEp cells. Values normalized to no IFN treatment (dotted line); n=3, means and SD shown. (I) Western blots of HBEp whole cell lysates (WCLs) probed
for TRIM22 and Mx1 expression. Actin is shown as a loading control. (J) Quantitation of western blots (as in J). Values normalized to actin and expressed relative to no
IFN treatment (dotted line); n=3, means and SD shown.Frontiers in Cellular and Infection Microbiology | www.frontiersin.org September 2021 | Volume 11 | Article 6897077
Charman et al. TRIM22 Confers Pre-Existing Immunity to IAVrespiratory epithelia (Figures 2C, E). We next examined how
TRIM22 expression in HBEp cells responded to IFN stimulation.
The addition of IFN-b caused an intense upregulation of the ISG
Mx1 at both the transcript and protein level. In contrast,
TRIM22 expression in the same cells was only moderately
increased at the transcript level and not substantially increased
at the protein level (Figures 2H–J). Together, these data
demonstrate TRIM22 to be constitutively expressed in primary
cells of lung origin independently of infection or immune
stimulation. Collectively, these data suggest that endogenous
levels of TRIM22 could potentially act as a pre-existing
antiviral defence against respiratory airway infection.
Constitutive Expression of TRIM22 Occurs
in a Cell-Type Dependent Manner
While we could demonstrate constitutive levels of TRIM22
expression in primary HBEp cells, these cells are challenging to
maintain in quantities suitable for functional studies due to the
onset of cellular senescence. Accordingly, to identify a tractable
cell line that maintained the constitutive profile of endogenous
TRIM22 expression observed in the airway, we screened a panel
of human cell lines for TRIM22 expression with or without IFN-
b stimulation. In all transformed cell lines examined (HEK 293T,
HeLa, HEp2, and A549), TRIM22 was either absent or only
detected following IFN-b stimulation, as observed for the ISG
Mx1 (Figures 3A–D and Figure S1A, B). This was surprising
and indicated that infection studies that utilized such cell lines
would not capture the potential antiviral properties of
endogenous TRIM22 observed in the respiratory tract
(Figures 1, 2). In contrast, both primary and hTERT (human
telomerase reverse transcriptase) immortalized human lung
fibroblasts (MRC5 and MRC5t, respectively) retained
constitutive levels of TRIM22 expression independently of
IFN- s t imu l a t i on (Figure s 3A–D ) . As s ing l e - c e l l
transcriptomics experiments have shown lung fibroblasts to be
susceptible to IAV infection in vivo (Steuerman et al., 2018), we
chose MRC5t cells as a model cell line to study the antiviral
properties of constitutive TRIM22 expression against
IAV infection.
As IAV infection is known to activate innate immune
pathways that lead to the induction of ISGs, we began by
investigating TRIM22 expression levels over a time course of
IAV infection (A/WSN/1933(H1N1), WSN; MOI 1 PFU/cell) in
MRC5t and A549 cells, which constitutively or inducibly express
TRIM22, respectively (Figures 3A, B). Relative to IFN
stimulation alone, ISG Mx1 expression was barely detectible at
8 hpi in both cell types (Figure 3E). In contrast, TRIM22 was
continuously expressed throughout the time course of infection
in MRC5t cells and remained undetectable in A549 cells,
although readily detected upon IFN stimulation (Figure 3E).
To investigate the conditions required for the induction of
TRIM22 in A549 cells, we infected cells (WSN; MOI 0.01
PFU/cell) over an extended time course of infection to allow
for multiple cycles of IAV replication that could stimulate the
activation of IFN-mediated immune defences (Tapia et al., 2013;
Killip et al., 2017; Russell et al., 2019). Under these conditions,Frontiers in Cellular and Infection Microbiology | www.frontiersin.org 8both TRIM22 and Mx1 were robustly detected by 48 hpi
(Figure 3F), indicative of the activation of IFN-mediated
innate immune defences and induction of ISG expression (Di
Pietro et al., 2013; Russell et al., 2019). We conclude that the
constitutive expression of TRIM22 occurs in a cell-type
dependent manner, with many laboratory-adapted cell lines
requiring prolonged periods of infection or immune
stimulation to produce detectible levels of TRIM22 expression.
Thus, cell types which constitutively express TRIM22 might
confer a pre-existing antiviral defence to respiratory
airway infection.
Constitutively Expressed TRIM22 Provides
a Level of Pre-Existing Defence Against
IAV Infection
As TRIM22 has been reported to act as a direct antiviral effector
protein of IAV infection through the targeted ubiquitination and
proteasome-dependent degradation of NP (Di Pietro et al., 2013;
Pagani et al., 2018), we reasoned that the constitutive expression
of this antiviral effector protein might provide cells with an
immediate level of protection against infection. We therefore
sought to explore the restrictive potential of cells that
constitutively expressed TRIM22 to restrict IAV replication.
We generated stable MRC5t cell lines expressing non-targeting
control and TRIM22-targeting short hairpin RNAs (shCtrl and
shTRIM22, respectively) sufficient to knockdown TRIM22
expression with or without IFN-b stimulation (Figures 4A, B).
To test our hypothesis, we infected shCtrl or shTRIM22 MRC5t
cells with a range of human (WSN; A/PR8/1934(H1N1), PR8; or
A/Udorn/1972(H3N2), Udorn) or avian strains (A/Duck/
Singapore/5/97(H5N3), Duck; or A/Chicken/Italy/1067/99
(H7N1), Chicken) of IAV and examined the number of NP
positive cells by indirect immunofluorescence at 8 hpi
(Figures 4C, D). Depletion of TRIM22 significantly increased
the number of IAV NP positive cells relative to infected control
cells for the majority of strains examined. Correspondingly, we
observed a significant increase in the number of IAV (WSN)
plaques in MRC5t cells depleted of TRIM22 relative to control
cells at 36 hpi under equivalent infection conditions (Figures 4E,
F). This increase in plaque formation occurred independently of
IFN signalling, as the addition of the JAK-STAT inhibitor
Ruxolitinib (Ruxo), which effectively blocked the induction of
ISG expression (Mx1 and ISG15) following IFN stimulation
(Figure S1C), had no effect on IAV plaque number in MRC5t
cells [Figure 4G; (Stewart et al., 2014)]. Thus, pre-existing levels
of TRIM22 expression are sufficient to restrict the initiation of
IAV infection independently of the IFN response.
In order to investigate the kinetics of TRIM22 restriction
further, we examined the point in the IAV replicative cycle at
which it acted. We infected TRIM22 depleted or control MRC5t
cells with IAV (PR8; MOI 0.2 PFU/cell) and harvested infected
cell extracts over a range of early time points covering the
initiating cycle of IAV infection. We used qRT-PCR and
western blotting to measure viral transcription and protein
expression of three gene products (NP, M1 and NS1) encoded
by independent genome segments. TRIM22 depletion increasedSeptember 2021 | Volume 11 | Article 689707
Charman et al. TRIM22 Confers Pre-Existing Immunity to IAVtranscription of all three genes (Figure 5A), correlating in each
case with an increase in viral protein synthesis (Figures 5B, C).
Correspondingly, we could observe an enhanced rate of de novo
vRNA synthesis by 6 hpi (Figure 5D). While transcription and
replication of the IAV genome are intimately linked, the
differences in mRNA levels were detectable prior to the
differences observed in vRNA synthesis (4 hpi vs 8 hpi,
respectively; Figures 5A, D). Thus, the suppression of viral
transcription by TRIM22 is likely responsible for, or
contributes to, the attenuation of IAV genome replication. To
assess the impact of TRIM22 on the spread of infection, we
infected TRIM22 depleted or control cells with IAV analysed the
production of infectious virus released from infected cells over a
time-course of infection. We observed an increase in infectious
virus produced in TRIM22 depleted cells compared to controlFrontiers in Cellular and Infection Microbiology | www.frontiersin.org 9cells, confirming TRIM22-mediating restriction is sufficient to
attenuate the replication and spread of IAV.
We conclude that constitutive levels of TRIM22 expression
confer a pre-existing level of antiviral defence to IAV infection,
which acts to supress IAV transcription within the first 4 hours
of infection prior to detectible levels of ISG expression and
independently of IFN-mediated innate immune defences
(Figures 3E, 4G).
Laboratory-Adapted Cell Lines
Demonstrate Alternate Patterns of
Immune Gene Expression Relative to
Bronchial Epithelial Cells
As we had identified the constitutive expression of TRIM22 to
occur in a tissue-specific and cell-type dependent mannerA B C
D
E F
FIGURE 3 | TRIM22 is differentially expressed in a cell-type dependent manner. (A–C) Primary and hTERT immortalized human lung fibroblast (MRC5 and MRC5t,
respectively), lung adenocarcinoma epithelial (A549), and SV40-transformed human kidney epithelial (HEK 293T; 293T) cells were treated with (+) or without (-) IFN-b
(100 IU/ml) for 24 h. (A) Western blots of WCLs probed for TRIM22 expression. Actin is shown as a loading control. (B, C) qRT-PCR quantitation of TRIM22 and
Mx1 mRNA transcript expression levels, respectively. Values normalized to MRC5t cells without IFN treatment (dotted line); n=3, means and SD shown. (D) Confocal
microscopy images of MRC5t and A549 cells with or without IFN treatment (as in A). TRIM22 was labelled by indirect immunofluorescence. Nuclei were stained with
DAPI. (E) MRC5t and A549 cells were mock-treated, IFN- b (100 IU/ml) stimulated or infected with IAV (A/WSN/1933(H1N1), WSN) at a MOI of 1 PFU/cell (based on
MDCK titres) for the indicated times (hours; h). WCLs were analyzed by western blots for TRIM22, Mx1, and viral protein (NP and NS1) expression. Actin is shown as
a loading control. (F) A549 cells were infected with IAV (WSN; MOI of 0.01 PFU/cell based on MDCK titres) and harvested at the indicated times prior to western
blotting (as in E).September 2021 | Volume 11 | Article 689707
Charman et al. TRIM22 Confers Pre-Existing Immunity to IAV(Figures 1–3), we next investigated if other antiviral regulators
showed similar patterns of differential expression in laboratory-
adapted cell lines. Although a functional characterization of these
effector proteins is outside the scope of this study, we wished to
establish whether the cell-type specific expression observed for
TRIM22 was unique or more widely applicable. Using RNA-Seq
data sets obtained from HPA [https://www.proteinatlas.org;
(Uhlen et al., 2010; Uhlen et al., 2015)], we compared the
transcript expression profile of human bronchial epithelial cells
(HBEC3) to that of three laboratory-adapted cell lines (A549,
HEK 293, and HeLa) widely used for respiratory virus research.
For each pairwise comparison, we identified more than 500
differentially expressed genes (DEGs) to be downregulated (≥
5-fold change) relative to HBEC3 cells (Figures 6A, B and
Supplemental Table S3A). Pathway analysis identified a
substantial proportion of these downregulated DEGs to map to
the immune system in each case [Figure 6B and Supplemental
Tables S3B-D); A549 (19.06%), HEK 293 (18.15%), and HeLa
(17.53%)]. Out of the 187 unique immune genes identified to be
downregulated relative to HBEC3 cells (Supplemental TablesFrontiers in Cellular and Infection Microbiology | www.frontiersin.org 10S3E, F), 47 (25.1%) were downregulated in all three laboratory-
adapted cell lines and 52 (27.8%) common to at least two cell
lines (Figures 6C, D; core and shared DEGs, respectively).
Notably, the identification of these DEGs occurred
independently of detectible levels of IFN expression in HBEC3
cells (Figure 6E and Supplemental Table S3G), indicating that
HBEC3 cells were not undergoing an innate immune response
that would lead to elevated levels of immune gene expression at
the point of RNA extraction. These data demonstrate that
laboratory-adapted cell lines to have downregulated patterns of
constitutive immune gene expression relative to bronchial
epithelial cells, with many immune genes being downregulated
in more than one cell type.
We next investigate if these alternate patterns of immune
gene expression could potentially influence the outcome of IAV
infection. We curated an extended IAV KEGG network
([hsa05164]) to include recently identified restriction factors
[Supplemental Table S4A; (Shim et al., 2017; Villalon-Letelier
et al., 2017)]. Out of the 184 genes analyzed, 36 (19.5%) were
identified to be downregulated (≥ 5-fold change) in at least oneA B C
D E F G
FIGURE 4 | Constitutive TRIM22 expression confers pre-existing antiviral immunity. MRC5t cells were stably transduced to express non-targeting control (shCtrl) or
TRIM22-targeting (shTRIM22) shRNAs (clones B7 to B9). (A) qRT-PCR quantitation of TRIM22 mRNA levels in MRC5t shCtrl and shTRIM22 cells. Values normalized
to shCtrl; n=3, means and SD shown. (B) MRC5t shCtrl and shTRIM22 (B7) cells were treated with (+) or without (-) IFN-b (100 IU/ml) for 24 h. WCLs were analysed
by western blotting for TRIM22 expression. Actin is shown as a loading control. (C, D) MRC5t shCtrl or shTRIM22 (B7) cells were infected with a panel of human
(WSN, A/Puerto Rico/8/1934(H1N1); PR8, and A/Udorn/307/1972(H3N2); Udorn) or avian (A/Duck/Singapore/5/1997(H5N3); Duck and A/Chicken/Italy/1067/1999
(H7N1); Chicken) IAVs at a MOI of 0.05 FFU/cell (based on MRC5t titres) for 8h. (C) Representative confocal micrographs of PR8 infected MRC5t shCtrl or shTRIM22
cells. TRIM22 and IAV NP were labelled by indirect immunofluorescence. Nuclei were DAPI stained. (D) Relative (Rel.) fold increase in the number of NP antigen
positive cells (shTRIM22/shCtrl) in IAV infected MRC5t cell monolayers. n ≥ 3, all data points shown; line, mean; whisker, SD. (E) Representative immunocytochemistry
images of IAV (WSN; 50-100 PFU/monolayer) plaque formation (NP staining) in MRC5t shCtrl and shTRIM22 cell monolayers. (F) Relative fold increase in IAV plaque
formation efficiency (PFE; shTRIM22/shCtrl) in MRC5t infected monolayers (as in E). n ≥ 3, all data points shown; line, mean; whisker, SD. (D, F) One sample two-tailed
t test against a theoretical mean of 1; p-values shown. (G) Quantitation of relative IAV (WSN) PFE (shTRIM22/shCtrl) in cell monolayers treated with Ruxolitinib (Ruxo;
4 µM) or DMSO (carrier control). Values normalized to infected shCtrl cell monolayers treated with DMSO (dotted line). All data points shown; line, mean; whisker SD.
Upper, two-tailed t test; lower, one sample two-tailed t test against a theoretical mean of 1; p-values shown.September 2021 | Volume 11 | Article 689707
Charman et al. TRIM22 Confers Pre-Existing Immunity to IAVcell line relative to HBEC3 cells (Figure 7A). Out of these, 8 were
downregulated in all three cell lines and 13 common to at least
two cell lines (Figures 7B, C). Importantly, the basal levels of
gene expression observed for these DEGs in HBEC3 cells were
similar to those observed in lung tissue (Figures 7C, D and
Supplemental Table S4B), indicating that these host factors
were downregulated in laboratory-adapted cell lines relative to
both bronchial epithelial cells and lung tissue. We next examined
the protein expression profile of a subset of these DEGs
(TRIM22, UBA7, IFITM1, GBP1, and IFIH1) by western
blotting. In each instance, significantly lower levels of protein
expression were detected in A549 cells relative to HBEC3 cells
(Figures 7E, F), confirming cell-type dependent patterns of
constitutive immune gene expression. We hypothesized that
such alternate patterns of immune gene expression may
influence the initiation or outcome of IAV infection in a cell-
type dependent manner. To examine this, we compared the
relative plaque titre of IAV in HBEC3 and A549 cells to that of
MDCK cells. Consistent with their pattern of immune gene
expression, HBEC3 cells were highly restrictive to IAV plaque
formation relative to both MDCK (≥ 70-fold) and A549 (≥ 30-
fold) cells under equivalent infection conditions (Figures 7G,
H). This cell-type dependent increase in IAV restriction occurred
independently of IFN-mediated innate immune defences, as the
addition of Ruxolitinib did not affect IAV plaque number in any
of the cell types examined [Figure 7I; (Stewart et al., 2014)];
although an increase in relative plaque size could be observed inFrontiers in Cellular and Infection Microbiology | www.frontiersin.org 11each instance (Figure 7J). Thus, we identify alternate patterns of
pre-existing immune gene expression to correlate with cell line
permissivity to IAV infection. Importantly, we show these pre-
existing levels of antiviral gene expression to be significantly
downregulated in many laboratory-adapted cell lines commonly
used for respiratory virus research relative to HBEC3 cells or
lung tissue, the natural site of infection. Whether there is a
common cause responsible for this loss of pre-existing antiviral
gene expression remains an interesting question for
future research.DISCUSSION
We hypothesized that tissues exposed to the constant threat of
infection may constitutively express higher levels of pre-existing
immune factors to reduce the need to activate potentially
harmful innate immune defences, thereby creating localized
patterns of antiviral protection. Here we identify lung tissue to
have enriched levels of constitutive ISG expression relative to
other mucosal and non-mucosal tissues (Figure 1). We identify
the antiviral host factor TRIM22 to be one of several antiviral
proteins to be constitutively expressed in lung tissue and primary
cells of lung origin independently of immune stimulation or IAV
infection (Figure 2). We show that the constitutive expression of
TRIM22 provides an element of pre-existing antiviral defence toA B
C D E
FIGURE 5 | Constitutive TRIM22 expression restricts the onset of IAV transcription. MRC5t shCtrl and shTRIM22 cells were infected with IAV (PR8) at a MOI of 0.2
(A–C) or 0.05 (D) PFU/cell (based on MRC5t titres) and harvested at the indicated time points. (A) qRT-PCR quantitation of IAV NP, M1, and NS1/NEP mRNA
levels. Values normalized to infected shCtrl samples at 4 hpi. n=3, means and SD shown. (B, C) Quantitation of viral protein (NP, M1, NS1) expression derived from
western blots of infected WCLs. Actin is shown as a loading control. Values normalized to actin and expressed relative to levels in infected shCtrl cells at 10 hpi. n=3,
means and SD shown. (A, B) One sample two-tailed t test against a theoretical mean of 1; p-values shown. (D) Quantification of IAV vRNA seg. 7 levels by qRT-
PCR. Values normalized to infected shCtrl samples at 0.25 hpi. n=3, means and SD shown. (E) MRC5t shCtrl and shTRIM22 cells were infected with IAV (WSN) at a
MOI of 0.001 PFU/cell (based on MRC5t titres). Media were harvested at the indicated time points and IAV plaque titre determined on MDCK cells; n=3, means and
SD shown. (D, E) ratio paired two-tailed t test; p-values shown.September 2021 | Volume 11 | Article 689707
Charman et al. TRIM22 Confers Pre-Existing Immunity to IAVIAV infection independently of IFN-mediated innate immune
defences (Figures 3, 4).
Our finding that TRIM22 is one of the most abundantly
expressed TRIM proteins in lung tissue came as a surpriseFrontiers in Cellular and Infection Microbiology | www.frontiersin.org 12(Figures 1, 2), as the expression of TRIM22 has been widely
reported to require viral infection or immune stimulation in
multiple cell culture model systems [Figure 3 and Figure S1;
(Hattlmann et al., 2012; Di Pietro et al., 2013)]. Although we doA B
C D
E
FIGURE 6 | Laboratory-adapted cell lines have downregulated levels of constitutive immune gene expression relative to human bronchial epithelial cells. (A) Scatter plots
showing differentially expressed gene (DEG) transcripts identified to be downregulated (blue circles; ≥ 5-fold change, diagonal blue line) in A549, HEK 293, and HeLa (top,
middle, and bottom panels, respectively; vertical blue line, ≤ 4 TPM) relative to HBEC3 cells (horizontal blue line, ≥ 3 TPM). Values shown in Supplemental Table S3A.
(B) Reactome pathway analysis of mapped DEGs (identified in A). The top 15 most significantly enriched pathways plotted (-log10 FDR shown; Supplemental Tables
S3B-D). Dotted line, threshold of significance (-log10 FDR of 0.05). The number of downregulated DEGs identified and immune system percentile shown (blue and red
text, respectively). (C) Venn diagram showing the number of unique and shared immune system DEGs (identified in B; Supplemental Table S3E) for each paired
condition analyzed. (D) Heat map showing the expression profile (log2 TPM) of conserved (core, 47 genes) or shared (52 genes) immune system DEGs (as in C). Every
second gene labelled. Values shown in Supplemental Table S3F. (E) Heat map showing IFN-related receptor and cytokine expression profiles (log2 TPM) in A549,
HEK 293, HeLa, and HBEC3 cells. Values shown in Supplemental Table S3G.September 2021 | Volume 11 | Article 689707
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FIGURE 7 | Laboratory-adapted cell lines show enhanced permissivity to IAV infection. (A) Heat map showing the expression profile (log2 TPM) of genes associated
with an extended IAV KEGG network [hsa05164; (Villalon-Letelier et al., 2017)] in HBEC3, A549, HEK 293, and HeLa cells. Every second gene labelled. Values shown
in Supplemental Table S4A. (B) Venn diagram showing the number of unique and shared DEGs identified to be downregulated (≥ 5-fold change) in A549, HEK 293,
and HeLa cells (≤ 4 TPM) relative to HBEC3 cells (≥ 3 TPM per gene) for each paired condition analyzed. (C) Heat map showing expression profile (log2 TPM) of
conserved (core, 8 genes) and shared (13 genes) DEGs identified to be downregulated in A549, HEK 293, and HeLa cells relative to HBEC3 cells (as in B) and
associated values in lung tissue (GTEx, n=427). Values shown in Supplemental Table S4B. (D) Violin plot showing the expression profile of downregulated IAV KEGG
DEGs (as in C). Horizontal solid lines; median gene expression. Horizontal dotted lines; 5th and 95th percentile range. Paired one-way ANOVA (Friedman multiple
comparison test); p-values shown. (A–D) Data adapted under creative commons licence from HPA and GTEx portal, respectively (Uhlen et al., 2010; Carithers et al.,
2015; Uhlen et al., 2015). (E) Western blots of WCLs derived from non-treated HBEC3 and A549 cells showing UBA7, GBP1, IFIH1, TLR3, IFITM1, and TRIM22 (+ve
control) protein expression levels. Actin is shown as a loading control. (F) Quantitation of protein expression levels (as in E). Values normalized to actin and expressed
relative to levels in HBEC3 cells (Dotted line). n≥3, means and SD shown. One-sample two-tailed t test against a hypothetical mean of 1; p-values shown. (G)
Representative immunocytochemistry images of IAV plaque formation (NP staining) in MDCK, A549, and HBEC3 cells infected with equivalent serial dilutions of IAV
(WSN). (H) Quantitation of plaque numbers in each cell line expressed relative (rel.) to MDCK cells (rel. plaque titre); n≥3, means and SD shown. Mann-Whitney U-test;
p-value shown. (I) MDCK, A549, and HBEC3 cells were pre-treated for 1 h in the presence of Ruxolitinib (Ruxo; 5 µM) or DMSO (carrier control) prior to infection with
serial dilutions of IAV (WSN) in the presence of drug or carrier control. Quantitation of rel. plaque titre (plaque titre with Ruxo/plaque titre with DMSO) for each cell line is
shown. n≥3, means and SD shown. One-sample two-tailed t test against a hypothetical mean of 1; p-values shown. (J) Quantitation of the fold increase in IAV plaque
diameter in Ruxo or DMSO-treated infected cell monolayers (as in I). Values normalized to the median DMSO plaque diameter in each cell line (DMSO or Ruxo/median
DMSO). n≥3, means and SD shown. Mann-Whitney U-test; p-values shown.Frontiers in Cellular and Infection Microbiology | www.frontiersin.org September 2021 | Volume 11 | Article 68970713
Charman et al. TRIM22 Confers Pre-Existing Immunity to IAVnot know the genetic or biological causes responsible for the
differential patterns of TRIM22 expression observed, we note
that TRIM22 (formerly known as Staf50) has been shown to be
upregulated by other cytokines, including interleukins-1b, -2 and
-15, progesterone, and tumour necrosis factor-a (Hattlmann
et al., 2012). Tonic IFN-signalling by host microbiota may also
contribute to the high levels of TRIM22 expression observed in
lung tissue (Figures 1, 2), as the antibiotic treatment of animals
has been shown to influence lung ISG expression levels in an
IFN-receptor dependent manner (Bradley et al., 2019; Stefan
et al., 2020). However, the presence of host microbiota in vivo
does not account for the cell-type dependent profiles of TRIM22
or ISG expression observed between cultured cells (Figures 3, 6,
and 7), which indicate an additional level of genetic regulation.
Notably, TRIM22 expression has been shown to be regulated by
p53 and found to correlate with cellular differentiation and
proliferation status (Obad et al., 2004; Hattlmann et al., 2012).
Thus, the downregulation of TRIM22 expression in many
laboratory-adapted cell lines may occur due to alternative
patterns of cytokine expression, p53 inactivation, and/or
sustained cellular proliferation in a cell-type dependent
manner. It is also evident that many carcinoma cell lines carry
variable gene copy numbers and single nucleotide
polymorphisms (SNPs) which can influence protein expression
levels and immune competence (Barretina et al., 2012; Frishberg
et al., 2019; Ghandi et al., 2019). Indeed, Cancer Cell Line
Encyclopaedia [CCLE; (Barretina et al., 2012; Ghandi et al.,
2019)] records demonstrate TRIM22 transcript levels and copy
number are downregulated in many lung carcinoma cell-types
(https://portals.broadinstitute.org/ccle/page?gene=TRIM22). We
note that transformed cell lines which lack constitutive TRIM22
expression include many model cell lines currently used for
respiratory virus research. As intrinsic immunity contributes to
the resistance of cells to infection (Bieniasz, 2004; Komatsu et al.,
2016; Wu et al., 2018; Alandijany, 2019; Bergantz et al., 2019), it
seems plausible that adoption of cell types suited to high levels of
virus propagation may have unwittingly selected for cells that fail
to express one or more intrinsic antiviral effector molecules. Such
differences may therefore account for some of the experimental
variation debated in the scientific literature between cell
culture systems.
Previous reports have demonstrated that TRIM22 can
function as a direct-acting antiviral effector protein against a
wide variety of DNA and RNA pathogens (Barr et al., 2008; Eldin
et al., 2009; Gao et al., 2009; Hattlmann et al., 2012; Di Pietro
et al., 2013; Yang et al., 2016). In the context of IAV, the IFN-
stimulated induction of TRIM22 has been shown to mediate IAV
restriction in A549 cells through the ubiquitination of NP
leading to its proteasome-dependent degradation (Di Pietro
et al., 2013; Pagani et al., 2018). NP is an essential component
of vRNPs, required for viral gene expression, genome replication,
and de novo vRNP assembly (Eisfeld et al., 2015; Hutchinson,
2018). Our data corroborate that TRIM22 functions as an
antiviral effector against IAV infection, likely enacted through
its ability to target NP for degradation as previously reported (Di
Pietro et al., 2013; Pagani et al., 2018). However, unique from itsFrontiers in Cellular and Infection Microbiology | www.frontiersin.org 14reported role as an effector protein of the IFN-response, we
demonstrate that pre-existing levels of constitutive TRIM22
expression are sufficient to restrict the onset of IAV
transcription from the outset of infection (Figure 5A).
We propose that the pre-existing antiviral defence conferred
by constitutive expression of TRIM22 may play an important
role in protecting the host during the initial exposure of
respiratory cells to invading virus, prior to the spread of
infection and activation of the innate immune response. Our
observation that TRIM22 restricts the number of productive
infectious events following IAV challenge suggests that this pre-
existing defence can influence the outcome of infection in
individual cells (Figure 4). This may be particularly relevant
when host tissues are exposed to low levels of virus challenge.
Our observation that constitutive TRIM22 also restricts the
spread of virus infection suggests that this pre-existing defence
may also play a valuable role in slowing down the rate of IAV
replication prior to activation of additional host defences
(Figure 5E). The presence of such pre-existing antiviral
defences is likely to provide additional advantages over
pathogen-induced immunity. Firstly, many viruses encode
antagonists of immune signalling that can inhibit or attenuate
the induction of host immune responses (Hale et al., 2010; Hsu,
2018). Thus, in the evolutionary arms race between virus and
host, the constitutive expression of key antiviral factors may
provide a valuable initial defence that cannot be counteracted by
simply supressing host transcription. Secondly, the ability to
immediately limit infection may reduce the need to upregulate
potentially harmful pro-inflammatory immune responses that
can themselves contribute to host pathology, as is the case for
severe IAV respiratory disease and ARDS (acute respiratory
distress syndrome) following SARS-CoV-2 (severe acute
respiratory syndrome coronavirus 2) infection (La Gruta et al.,
2007; Iwasaki and Pillai, 2014; Liu et al., 2016; Wu et al., 2020;
Zhu et al., 2020).
We propose that TRIM22 likely functions along with other
known constitutively expressed antiviral effector proteins, for
example TRIM32 and TRIM41, which have been shown to have
intrinsic antiviral functions against IAV (Fu et al., 2015; Patil
et al., 2018). The identification of additional ISGs, including
BST2, IFITM1, SAMHD1, and GBP family members, that
demonstrate tissue-specific and cell-type dependent (Figures 1,
7) patterns of constitutive expression raises the possibility that
other antiviral proteins may also contribute to this pre-existing
defence. Given that TRIM22 is reported to restrict multiple
different viruses, it is tempting to speculate that pre-existing
levels of TRIM22 expression might also be relevant to the control
of other important respiratory viruses. Thus, we anticipate that
our findings will provide a foundation for future work that could
further develop the concept of intrinsic immunity within cells of
the respiratory airway.
In conclusion, we identify tissue-specific and cell-type
dependent patterns of constitutive TRIM22 expression in the
respiratory tract to confer a pre-existing intracellular defence to
IAV replication. We show TRIM22 to be among many antiviral
effector molecules upregulated at this portal of viral entry andSeptember 2021 | Volume 11 | Article 689707
Charman et al. TRIM22 Confers Pre-Existing Immunity to IAVpropose that the importance of such constitutive levels of
antiviral gene expression in the control of respiratory
infections has yet to be fully appreciated.DATA AVAILABILITY STATEMENT
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